Emerging Company Showcase

1. October 19-20, 2016
Innovation Quality Service
Sinovet (Beijing)
Biotechnology Co., Ltd
Shucheng Zhang, DVM, PhD

2. Sinovet
• A private research-based company
• Business focus: Animal biological
product development, manufacture,
and marketing
• Company core value: innovation,
quality, and service

3. Sinovet (Beijing)
Biotechnology Co., Ltd，
Sinovet (Jiangsu)
Biopharmaceutical Co., Ltd
China Medical City，
Taizhou
Sinovet Sites

4. Fact of Sinovet
 Sinovet (Beijing) was established in 2010 after splitting from another
biological company (Headquarter + Marketing)
 Sinovet (Jiangsu) was established in 2011 in China Medical City in
Taizhou, Jiangsu ( Production + R&D + Marketing)
 Major business units: R&D, Production, and Marketing
 Employee: 200 plus
 Investment Capital : US$ 30 millions
 Revenue (2015) : US$ 10 millions

5. Board of Directors
Wu, Hua
Chairman,
President
Zhao, Jianzeng
Director
Vice-President
Marketing
Wu, Qiong
Director
Vice-President
HR and Finance
Wang, Wei
Secretary，
GM，R&D
Regulatory
Business
Zhang,
Shucheng
Director
Vice-President
Manufacture
and R&D

6. Company Structure
Board of
Directors
President
Marketing R&D Center Production
Legal/
Business
Finance HR

7. Wu, Hua
President , CEO
Zhao,
Jianzeng
VP, Marketing
Lu, Wei
General Manager,
South China
Regions
Tian, Changxiao
General Manager
Key Customer
Account
Chen, Lei,
General Manager,
North China
Regions
Shi, Xinchuan
General Manager
Bovine Products
Zhang, Shucheng
VP, R&D,
Production
Su, Weiwei,
General Manager,
Sinovet (Jiangsu),
Production, QC, QA
Wang, Wei
General Manager，
R&D RA, Business,
Networking
Xia Mingqi
Associate General M，
R&D Swine Diseases
He, Yanliang
Associate General M,
R&D Small Animal
Diseases
Li, Zhenguang
Associate General M,
R&D Bovine Diseases
Wu, Qiong
VP, HR,
Finance
Wu，Yingying
Associate General
Manager, Finance
Xu, Jianjun
Manager, Human
Resource
Sinovet Leadership Team

8. Milestones of Sinovet
2013
2010
2011
2012 2014 2016
2015
Sinovet
(Beijing)
established
Sinovet (Jiangsu)
established
HP PRRS vaccine
licensed
HP-PRRS/CSF
combo vaccine
clinical trial
Two production
lines accredited
for GMP
HP PRRS-
CSF combo
vaccine
licensed
Two more production lines
accredited for GMP
PRV, HP-PRRS (bioreactor),
BVD licensed
First product (CSF) on market
Sinovet (Jiangsu)
construction
completed

9. R&D Center
 Research Teams: 35+ scientists
 Research Focus: Animal (swine, bovine, C&A )
vaccines and diagnostic reagents/kits
 Key Technologies/resources
 Suspension cell technology
 Lyophilization/Stabilizer platform
 Genetic engineering technology
 Network and collaborations
 Local strain access and acquisition through surveillance
program

10. R&D Center
R&D Center
Swine
HP–PRRS
Live
PRRS-CSF
Combo
PRRS-CSF-
PRV Combo
PRRS-PRV
combo
SIV
PCV2
Bovine
BVD, Killed
BVD-IBR
Killed
BVD-IBR Live
Bovine Multiple
Combo
Small
Animal
MEV-CDV
live
Bacterial
Vaccines
Rabies
Technology
Suspension
cells
Adjuvant
Vaccine
Processing
Business/
Regulatory
Regulatory
Affairs
IP
Networking
Business and
Legal
Diagnosis
Monoclonal
antibodies
Diagnostic
kits
Tech service
support

11. R&D Laboratories

12. R&D Teams

13. Sinovet Pipelines
Post
2020
Pre 2014 2015 2016 2017 2018 2019
PCV2
M. hyo
PCV2/M. hyo combo
PED/TGE combo
Cattle 5-way vaccine
Diagnostic kits

14. S
Sinovet New Product Projection
0
2
4
6
8
10
12
14
16
18
20
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2011
Existing products New Products
NumberofProducts

15. Innovation Example I
HP-PRRS/CSF Live Combo Vaccine
Innovation Points:
• First PRRS/CSF combo vaccine
• Most safe vaccine HP PRRSV strain with
double gene deletions
• PRRS vaccine strain without
immunosuppression and interference to
other vaccines
• Innovation testing method for CSF final
product

16. Innovation Example II
Suspension Cell Technology
MDCK
Cells
Marc-145
Cells
Adherence Cells Suspension Cells
Highlights:
- Serum free
medium
- No micro-
carrier
- High virus
titer
- Proprietary
technology

17. Intellectual Properties
• Chinese patents
• Published - 12
• Pending application - 4
• International patents
• Published - 3 (filed in 15
countries )
• Pending application - 1
• Trademarks
• Approved - 1
• Pending applications - 25

18. Manufacture

19. M
Manufacture Team

20. Production Capacity and
Production Lines
Capacity of production facility （400 M）
• Live viral vaccine - 200 million dose
• Killed viral vaccine – 120 million dose
• Killed bacterial vaccine – 80 million dose
GMP-certified production lines
 Live virus vaccine (Roller Bottles)
 Live virus vaccine (Bioreactors)
 Killed virus vaccine (Roller Bottles)
 Killed bacterial vaccine (Fermenter)
Production lines to be established
(phase II)
 Killed virus vaccine (Bioreactors)
 Live bacterial vaccine

21. Manufacture Space and Environment 冻干系统

22. Bioreactors (500L)

23. Vaccine Mixing and Assembly Lines

24. Product Quality Control
• Experienced
management
Team
• Well-trained
team for each
position
• State-of-art
Facility
• Strictly
enforced GMP
system
Manufacture/
Management
Quality Control Quality
Assurance
• Raw material
• Package
materials
• Antigen batches
and critical
reagents
• Final product
• Regular
environment
monitoring
• Water system
• Manufacture
process and
environment
• Water and gas
supply system
• Product release
process
• Costumer
feedback
• Documentation
system

25. Marketing and Technical Service

26. Marketing and Technical Service
Organization
Marketing
Sales
South
China
North
China
Large
Farms
Technical
Service
Tech
Service
Team
Diagnostic
Lab

27. Training and Technical Service

28. Major Partners and Collaborators
 Institute of Veterinary Drug Control
 Pfizer (Zoetis) Animal Health
 Tiankang Animal Health
 China Animal Husbandry Group

29. Government Sponsored Researches
Name of Project Sponsors Funding
Studies on diagnostic technology of cattle and
sheep
MOST US$ 200K
Studies on prevention/control technology of
major infectious diseases of cattle and sheep
MOST US$ 1000K
Stress effect on bovine respiratory diseases MOST US$ 200K
Studies on lyophilization/stabilizer for cattle
vaccines
MOST US$ 500K
Studies on animal vaccine technology MOST US$ 200K
Studies on cell suspension for animal vaccine
development
MOA US$ 170K
Industrialization research on CSF/PRRS
combo vaccine
JPST US$ 900K
PRSSV differential diagnosis JPST US$ 40K
MOST: Ministry of Science and Technology; MOA: Ministry of Agriculture; JPST: Jiangsu Province
Science and Technology Department

30. Research Collaborations with
Universities and Research Institutes

31. Research Collaborations with
University and Research Institutes

32. Collaborations with Pfizer/Zoetis

33. Collaborations with Animal Health
Companies

34. Sinovet - A Leader for Future

35. THANK YOU
Website: www.sinovetah.com